Published online 4 July 2008
Haematologica, Vol 93, Issue 9, 1389-1393 doi:10.3324/haematol.12964
Copyright © 2008 by Ferrata Storti Foundation

This Article Full Text Full Text (PDF) Ernst et al. . Supplementary appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Ernst, T. Articles by Müller, M. C. Search for Related Content PubMed PubMed Citation Articles by Ernst, T. Articles by Müller, M. C.

Chronic Myeloid Leukemia

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Thomas Ernst, Jana Hoffmann, Philipp Erben, Benjamin Hanfstein, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus, Martin C. Müller

III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany

Correspondence: Thomas Ernst, III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str. 7–11, 68305 Mannheim, Germany. E-mail:thomas.ernst{at}med3.ma.uni-heidelberg.de

The BCR-ABL K247R change is based on a rare single nucleotide polymorphism occurring likewise in healthy controls and non-hematologic cell types. Despite its juxtaposition to the P-loop, functional analysis showed no alteration compared to non-mutated BCR-ABL. We sought to investigate if other changes in the BCR-ABL kinase domain should be considered as single nucleotide polymorphisms rather than acquired mutations. A total of 911 chronic myeloid leukemia patients after failure or suboptimal response to imatinib were screened for BCR-ABL kinase domain mutations. Single nucleotide polymorphism analysis was based on the search for nucleotide changes in corresponding normal, non-translocated ABL alleles by ABL allele-specific PCR following mutation analysis. In addition to the K247R polymorphism we uncovered five new single nucleotide polymorphisms within the BCR-ABL kinase domain; two of them led to amino acid changes. Single nucleotide polymorphisms could theoretically contribute to primary but not to secondary resistance to tyrosine kinase inhibitors and must therefore be distinguished from acquired mutations. Novel point mutations should be confirmed by analyzing the normal ABL alleles to exclude polymorphisms.

Key words: single nucleotide polymorphism, polymorphism, BCR-ABL mutation, imatinib resistance, chronic myeloid leukemia.

This article has been cited by other articles:

				M. C. Muller, J. E. Cortes, D.-W. Kim, B. J. Druker, P. Erben, R. Pasquini, S. Branford, T. P. Hughes, J. P. Radich, L. Ploughman, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations Blood, December 3, 2009; 114(24): 4944 - 4953. [Abstract] [Full Text] [PDF]

				T. Hughes, G. Saglio, S. Branford, S. Soverini, D.-W. Kim, M. C. Muller, G. Martinelli, J. Cortes, L. Beppu, E. Gottardi, et al. Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase J. Clin. Oncol., September 1, 2009; 27(25): 4204 - 4210. [Abstract] [Full Text] [PDF]

				T. Ernst, F. X. Gruber, O. Pelz-Ackermann, J. Maier, M. Pfirrmann, M. C. Muller, I. Mikkola, K. Porkka, D. Niederwieser, A. Hochhaus, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib Haematologica, September 1, 2009; 94(9): 1227 - 1235. [Abstract] [Full Text] [PDF]

				T. P. Hughes and S. Branford Monitoring disease response to tyrosine kinase inhibitor therapy in CML Hematology, January 1, 2009; 2009(1): 477 - 487. [Abstract] [Full Text] [PDF]